The clinical evidence is still developing. There are promising studies on NAD+ and mitochondrial function, cognitive performance, and cellular repair, but large-scale, FDA-level clinical trials are still limited. That brings us to DirectMeds, one of the fastest-growing telehealth platforms in the United States, and their NAD+ injection program specifically.